Tags : Nash


Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH

Shots: Hanmi to receive $10M up front, $860M as development, regulatory approval, and commercialization of efinopegdutide along with royalties on sales of the approved product Merck to receive an exclusive license to develop, manufacture and commercialize efinopegdutide in the US and globally while Hanmi to retain an option to commercialize the therapy in Korea Efinopegdutide […]Read More


Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH

Shots: Pliant to receive $80M including upfront & equity investment and eligible to receive development, regulatory and commercial milestones with royalties on sales. Novartis to get exclusive WW license for Pliant’s PLN-1474 and up to three additional candidates Novartis will be responsible for all future development, manufacturing and commercial activities, a post-P-I study of PLN-1474, […]Read More


Gilead and Novo Nordisk Collaborate to Conduct a Combination Therapy

Shots: Gilead collaborates with Novo for the onset of a clinical trial combining its Firsocostat and Cilofexor with Novo’s Semaglutide for the treatment of patients with Nonalcoholic Steatohepatitis (NASH) The focus of the collaboration is to combine Gilead and Novo’s expertise for the enhancement of research capabilities and approaches developing novel therapies in NASH Semaglutide […]Read More